Volume 24 Issue 2
Feb.  2026
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2026  >  24(2): 251-254
HE Yuxuan, WANG Huaping, ZHAO Shiyong, ZHAN Lu. Clinical efficacy and safety of doxycycline in pediatric pertussis[J]. Chinese Journal of General Practice, 2026, 24(2): 251-254. doi: 10.16766/j.cnki.issn.1674-4152.004372
Citation: HE Yuxuan, WANG Huaping, ZHAO Shiyong, ZHAN Lu. Clinical efficacy and safety of doxycycline in pediatric pertussis[J]. Chinese Journal of General Practice, 2026, 24(2): 251-254. doi: 10.16766/j.cnki.issn.1674-4152.004372
shu

Clinical efficacy and safety of doxycycline in pediatric pertussis

doi: 10.16766/j.cnki.issn.1674-4152.004372
  • 1.

    Zhejiang Chinese Medical University, the Second School of Clinical Medicine, Hangzhou, Zhejiang 310053, China

Funds:

 2023KY202

  • Received Date: 2025-03-29
    Available Online: 2026-04-11
    Abstract
  •   Objective  To explore the efficacy and safety of doxycycline in treating pertussis in children aged 8 years and above.  Methods  A retrospective analysis was conducted on 166 children aged ≥ 8 years with pertussis who attended the pediatric outpatient department of Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine from December 2023 to May 2024. According to the antibiotics selected, patients were divided into the azithromycin group (62 cases), the trimethoprim sulfamethoxazole (TMP-SMZ) group (48 cases), and the doxycycline group (56 cases). The clinical efficacy, time to symptom relief, and incidence of adverse reactions were compared among the three groups.  Results  The azithromycin group showed 9 cases of significant effectiveness, 11 cases of effectiveness, and 42 cases of ineffectiveness, with a total effective rate of 32.25%. The TMP-SMZ group demonstrated 14 cases of significant effectiveness, 26 cases of effectiveness, and 8 cases of ineffectiveness, yielding a total effective rate of 83.33%. In the doxycycline group, 18 cases were significantly effective, 26 cases were effective, and 12 cases were ineffective, with a total effective rate of 78.57%. The total effective rate of the azithromycin group was lower than that of the other two groups (P < 0.001 after Bonferroni correction). The times to symptom relief time in the azithromycin, TMP-SMZ, and doxycycline groups were (13.05±4.23) days, (11.00±2.30) days, and (11.23±2.59) days, respectively, with the azithromycin group showing a significantly longer duration (P < 0.05). In terms of adverse reactions, 11 cases in the azithromycin group and 5 cases in the doxycycline group had gastrointestinal symptoms. In the TMP-SMZ group, 14 patients developed adverse reactions, including 4 with gastrointestinal symptoms and 10 with rashes. The TMP-SMZ group had higher incidences of rash and total adverse reactions compared to the doxycycline group (P < 0.017 after Bonferroni correction).  Conclusion  Doxycycline can effectively alleviate symptoms in children aged 8 years and older with pertussis, with fewer adverse reactions, supporting its clinical application value.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    ZHANG J, DENG J, YANG Y, et al. Pertussis vaccination in Chinese children with increasing reported pertussis cases[J]. Lancet Infect Dis, 2022, 22(1): 21-22.
    [2]
    HU Y, GUO M, YAO K, et al. Infections in preschool and school-aged children are driving the recent rise in pertussis in China[J]. J Infection, 2024, 88(6): 106170. DOI: 10.1016/j.jinf.2024.106170.
    [3]
    李宏森, 梁疆莉, 杨净思. 百日咳流行病学特征及防控进展[J]. 中国生物制品学杂志, 2024, 37(3): 361-369.

    LI H S, LIANG J L, YANG J S. Epidemiological characteristics and prevention progress of pertussis[J]. Chinese Journal of Biologicals, 2024, 37(3): 361-369.
    [4]
    MIGUELENA B, DE K, SWAMINATHAN G, et al. Bordetella bronchiseptica and Bordetella pertussis: similarities and differences in infection, immuno-modulation, and vaccine considerations[J]. Clin Microbiol Rev, 2023, 36(3): e0016422. DOI: 10.1128/cmr.00164-22.
    [5]
    中华人民共和国国家卫生健康委员会. 百日咳诊疗方案(2023年版)[J/CD]. 新发传染病电子杂志, 2024, 8(3): 86-88.

    National Health Commission of the People ' s Republic of China. Diagnosis and treatment plan for pertussis (2023 Edition)[J/CD]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(3): 86-88.
    [6]
    FENG Y, CHIU C, HEININGER U, et al. Emerging macrolide resistance in Bordetella pertussis in mainland China: findings and warning from the global pertussis initiative[J]. Lancet Reg Health West Pac, 2021, 8: 100098. DOI: 10.1016/j.lanwpc.2021.100098.
    [7]
    姚开虎, 孟庆红, 史伟, 等. 国内当前百日咳治疗的抗菌药物选择之我见[J]. 中华实用儿科临床杂志, 2024, 39(2): 85-88.

    YAO K H, MENG Q H, SHI W, et al. Thoughts on the selection of antimicrobials for current pertussis treatment in China[J]. Chin J Appl Clin Pediatr, 2024, 39(2): 85-88.
    [8]
    中华医学会全科医学分会, 中华医学会杂志社, 中华医学会《中华全科医师杂志》编辑委员会, 等. 咳嗽公众教育中国专家共识(第一版)[J]. 中华全科医师杂志, 2024, 23(4): 331-344.

    Chinese Society of General Practice, Chinese Medical Journals Publishing House, Editorial Board of Chinese Journal of General Practitioners of Chinese Medical Association, et al. Chinese expert consensus of public education on the knowledge of cough (first edition)[J]. Chinese Journal of General Practitioners, 2024, 23(4): 331-344.
    [9]
    MOHAMED F, MANIVANNAN K, FERNANDEZ C. Bordetella pertussis[J]. Trends Microbiol, 2023, 31(11): 1192-1193. doi: 10.1016/j.tim.2023.03.012
    [10]
    康利民, 米荣, 崔小岱, 等. 儿童重症百日咳临床特征及其影响因素分析[J]. 医学研究杂志, 2024, 53(4): 97-100, 196.

    KANG L M, MI R, CUI X D, et al. Clinical characteristics and influencing factors of severe pertussis in children[J]. Journal of Medical Research, 2024, 53(4): 97-100, 196.
    [11]
    GUO M, HU Y, MENG Q, et al. Resurgence and atypical patterns of pertussis in China[J]. J Infect, 2024, 88(4): 106140. DOI: 10.1016/j.jinf.2024.106140.
    [12]
    VENDITTO J, FEOLA J. Delivering macrolide antibiotics to heal a broken heart-and other inflammatory conditions[J]. Adv Drug Deliver Rev, 2022, 184: 114252. DOI: 10.1016/j.addr.2022.114252.
    [13]
    LI J, LIU L, ZHANG H, et al. Severe problem of macrolides resistance to common pathogens in China[J]. Front Cell Infect Microbiol, 2023, 13: 1181633. DOI: 10.3389/fcimb.2023.1181633.
    [14]
    PAYNE M, XU Z, HU D, et al. Genomic epidemiology and multilevel genome typing of Bordetella pertussis[J]. Emerg Microbes Infect, 2023, 12(2): 2239945. DOI: 10.1080/22221751.2023.2239945.
    [15]
    王要, 何丽婷, 陈乐园, 等. 复方磺胺甲恶唑治疗儿童百日咳效果观察[J]. 中华全科医学, 2024, 22(4): 614-617. doi: 10.16766/j.cnki.issn.1674-4152.003463

    WANG Y, HE L T, CHEN L Y, et al. Effect observation of compound sulfamethoxazole in the treatment of pertussis in children[J]. Chinese Journal of General Practice, 2024, 22(4): 614-617. doi: 10.16766/j.cnki.issn.1674-4152.003463
    [16]
    CIMOLAI N. Pharmacotherapy for Bordetella pertussis infection. Ⅱ. A synthesis of clinical sciences[J]. Int J Antimicrob Agents, 2021, 57(3): 106257. DOI: 10.1016/j.ijantimicag.2020.106257.
    [17]
    PREYRA R, EDDIN L E, AHMADI F, et al. Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: a systematic review and meta-analysis with active comparator disproportionality analysis[J]. Br J Clin Pharmacol, 2025, 91(6): 1632-1648. doi: 10.1002/bcp.70051
    [18]
    汪丙松, 姚开虎, 张贤溢, 等. 复方磺胺甲噁唑治疗儿童百日咳诱发皮疹的临床特征分析[J]. 中国当代儿科杂志, 2025, 27(10): 1227-1232.

    WANG B S, YAO K H, ZHANG X Y, et al. Clinical characteristics of trimethoprim-sulfamethoxazole-induced rash during treatment of pertussis in children[J]. Chinese Journal of Contemporary Pediatrics, 2025, 27(10): 1227-1232.
    [19]
    LI L, XIE T, XIAO L, et al. Compound sulfamethoxazole for pediatric pertussis: a retrospective cohort study in a region with high macrolide resistance[J]. Front Pediatr, 2025, 13: 1622467. DOI: 10.3389/fped.2025.1622467.
    [20]
    SINGH S, PRAVEEN A, KHANNA S. Computational modelling, functional characterization and molecular docking to lead compounds of Bordetella pertussis diaminopimelate epimerase[J]. Appl Biochem Biotechnol, 2023, 195(11): 6675-6693. doi: 10.1007/s12010-023-04413-0
    [21]
    NAEGER S, POOL V, MACINA D. Increased burden of pertussis among adolescents and adults with asthma or COPD in the United States, 2007 to 2019[J]. Chest, 2023, 165(6): 1352-1361.
    [22]
    吕芳, 曲东, 张瑾, 等. 北京地区单中心住院儿童百日咳的临床分析[J]. 医学研究杂志, 2021, 50(3): 64-67.

    LYU F, QU D, ZHANG J, et al. Clinical analysis of pertussis cases in hospitalized children in a single center of Beijing region[J]. Journal of Medical Research, 2021, 50(3): 64-67.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (6) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return